FemiClear acquired by Venture Life Group in women’s health push

By AI, Created 2:41 PM UTC, June 03, 2026, /AGP/ – FemiClear said June 3, 2026, that Venture Life Group plc has acquired the women’s intimate health brand and its CUROXEN line. The deal is set to expand distribution, support product innovation and broaden access to science-backed women’s health products in the U.S. and beyond.

Why it matters: - The acquisition gives FemiClear more scale to reach women with intimate health products backed by clinical study and science. - Venture Life gains a U.S. platform in a category tied to recurring and often stigmatized health needs. - The deal could help expand access to products for bacterial vaginosis, yeast infections, urinary health, vaginal wellness and genital herpes symptoms.

What happened: - FemiClear announced June 3, 2026, that Venture Life Group plc acquired the brand. - The transaction also includes CUROXEN, FemiClear’s science-backed wound and oral care brand. - Venture Life is an international self-care company that develops, manufactures and commercializes products for the global self-care market. - FemiClear said the deal marks a new phase of growth for the brand.

The details: - FemiClear has built a consumer base through clinically studied products aimed at common and recurring intimate health concerns. - The brand already sells through major U.S. retailers including Walmart, Walgreens, Target and CVS. - FemiClear said Venture Life backing should help deepen retail relationships, expand distribution, increase brand awareness and reach more women. - Caroline Goodner, CEO and co-founder of FemiClear, said the companies share a commitment to advancing women’s health. - Goodner said the transaction should expand trusted solutions to a broader audience and help accelerate growth. - Jerry Randall, founder and CEO of Venture Life Group plc, said FemiClear and CUROXEN fit Venture Life’s growing women’s health portfolio. - Randall said Venture Life already invests in women’s health through Balance Activ and Health & Her. - The acquisition brings Venture Life a U.S. team and platform it can leverage for future growth. - The partnership is intended to support continued investment in product innovation, clinical and consumer research, retail expansion and women’s health education. - FemiClear says its formulas are natural and patented. - The company says the brand was founded to address underserved and stigmatized women’s health concerns.

Between the lines: - Venture Life is using the deal to strengthen its U.S. presence in women’s self-care. - FemiClear appears to be trading independence for access to capital, distribution and broader commercial infrastructure. - The acquisition also signals continued interest in consumer health brands that combine science-backed positioning with retail-friendly products.

What’s next: - FemiClear plans to keep investing in innovation, research, distribution and education under Venture Life ownership. - Venture Life expects to use the U.S. platform to grow its existing brands and add new ones over time. - FemiClear said it will continue working to help women feel informed, supported and confident in managing intimate health. - The companies did not disclose financial terms in the release.